Areas of Focus
- Small Molecule Drug Design and Synthesis
Work Experience
- 2014-11~2019-02 - University of Michigan-Ann Arbor - Postdoctoral Researcher
- 2009-09~2014-07 - Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences - PhD Student
- 2005-09~2009-06 - Shandong Normal University - Bachelor's Student
Academic Background & Achievements
- 2009-09--2014-07 PhD: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- 2005-09--2009-06 Bachelor's: Shandong Normal University
Publications
- Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC degraders of Oncogenic KRASG12D, Tianfeng Xu, 2024
- Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Associate Domain (TEAD) PROTAC Degraders, Tianfeng Xu, 2024
- Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers, Tianfeng Xu, 2023
- Design, Synthesis, and Bioevaluation of Pyrido2,3-dpyrimidin-7-ones as Potent SOS1 Inhibitors, Tianfeng Xu, 2023
- Design, synthesis and structure-activity relationship studies of pyrido2,3-dpyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors, Tianfeng Xu, 2022
- Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations, Tianfeng Xu, 2022
- Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation, Tianfeng Xu, 2022
- Structure-based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction, Tianfeng Xu, 2019
- Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction, Tianfeng Xu, 2018
- A structure-guided optimization of pyrido2,3-dpyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties, Tianfeng Xu, 2017
- C5-substituted pyrido2,3-dpyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR(T790M) mutant, Tianfeng Xu, 2015
- Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as Selective Inhibitors of EGFR Threonine790—Methionine790 (T790M) Mutants., Tianfeng Xu, 2013
- Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido4,5-dpyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, Tianfeng Xu, 2013
- Pyrimido4,5-dpyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine(790) to Methionine(790) (T790M) Mutants, Tianfeng Xu, 2013
- Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine(790) -> Methionine(790) Mutant, Tianfeng Xu, 2012
Awards
- Guangdong Provincial Science and Technology Award (2016): Second Prize
- Guangzhou Science and Technology Award (2015): First Prize
